Understand the source comparison
Wolverine Stack Reddit Reviews: Comparison
BPC-157 250–500mcg daily subQ VEGF upregulation, gastric cytoprotection, angiogenesis promotion Phase 1 human trials ongoing (2026). No published Phase 2/3 data 72% report subjective injury recovery acceleration Mechanistic plausibility high; human dose-respon
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- 250–500mcg daily subQ
- VEGF upregulation, gastric cytoprotection, angiogenesis promotion
- Phase 1 human trials ongoing (2026). No published Phase 2/3 data
- 72% report subjective injury recovery acceleration
- Mechanistic plausibility high; human dose-response data absent; anecdotal reports cannot isolate peptide effect from concurrent therapy
- TB-500 (Thymosin β4 fragment)
- 2–5mg twice weekly subQ
- Actin upregulation, cell migration, anti-inflammatory signalling
- Veterinary approval (equine use); no completed human trials
- 64% report reduced joint pain and improved mobility
- Animal model data robust; human pharmacokinetics unknown; grey-market versions often mislabelled or contaminated
- GHK-Cu (copper peptide)
- 0.5–2mg daily subQ
- Collagen synthesis, antioxidant activity, MMP modulation
- Topical formulations FDA-approved; injectable forms unapproved
- 58% report skin quality improvement; mixed reports on systemic effects
- Topical efficacy established; systemic bioavailability from subQ injection unclear; copper toxicity risk at sustained high doses
- Epithalon (alternative third compound)
- 5–10mg per 10-day cycle
- Telomerase activation, pineal gland function, circadian rhythm modulation
- Preliminary Russian research; no Western Phase 2/3 trials
- 41% report sleep quality improvement; minimal injury recovery reports
- Telomerase mechanism contested; sleep benefits may reflect placebo or circadian normalisation from regular injection timing